Molecular Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Molecular Cancer Research 6, 119-126, January 1, 2008. doi: 10.1158/1541-7786.MCR-07-0090
© 2008 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Cao, Y.
Right arrow Articles by Kleinerman, E. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, Y.
Right arrow Articles by Kleinerman, E. S.

Signaling and Regulation

The Osterix Transcription Factor Down-Regulates Interleukin-1{alpha} Expression in Mouse Osteosarcoma Cells

Ying Cao1, Shu-Fang Jia1, Geetika Chakravarty2, Benoit de Crombrugghe3 and Eugenie S. Kleinerman1

1 Division of Pediatrics, 2 Department of Head and Neck Surgery, and 3 Department of Molecular Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Eugenie S. Kleinerman, Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Unit 87, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-8110; Fax: 713-794-5042. E-mail: ekleiner{at}mdanderson.org

K7M2 mouse osteosarcoma cells form lytic tumors and are deficient in osterix (Osx), a zinc finger–containing transcription factor required for osteoblast differentiation and bone formation. Our previous studies showed that replacement of Osx suppresses lytic bone destruction. Cytokines, including interleukin (IL)-1{alpha}, IL-6, IL-11, and prostaglandin E2, have been shown to stimulate osteoclast activity. We showed that IL-1{alpha} production by K7M2 cells was significantly suppressed following Osx transfection through a transcription-mediated mechanism. Osx had no effect on IL-6, IL-11, or prostaglandin E2. Site-directed mutagenesis and chromatin immunoprecipitation indicated that Osx down-regulated IL-1{alpha} through an Sp1-binding site on the IL-1{alpha} promoter. Inhibiting Osx by small interfering RNA in two cell lines (Dunn and DLM8) that expressed high levels of Osx led to enhanced IL-1{alpha} promoter activity and protein production and altered the phenotype from blastic to lytic. These data suggest that Osx down-regulates IL-1{alpha} expression in mouse osteosarcoma cells via transcriptional repression of IL-1{alpha} and this may in turn affect the lytic activity of the tumor cells. (Mol Cancer Res 2008;6(1):119–26)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2008 by the American Association for Cancer Research.